Currently, I would say, the closest to clinical practice technology of identifying rare cancer mutant alleles is a technology based on sequencing of cell-free DNA (cfDNA)  utilizing unique barcodes to each DNA molecule (actually each DNA fragment as cfDNA is fragmented. The problem with CTC is that, although it contains the whole genome DNA, it represents only a part of cancer tissue and this is a problem as cancer is often highly heterogeneous.